






## PEDIATRIK VRS ANATOMY

- Very small eye: Narrow space for maneuvers
  (15-19mm)
- Lens is relatively large
  - Vitreous-Retina relation!
  - Pars plana has not developed.
- Sclera is thin and elastic







## Sclerotomy

### DATA USED TO PLAN SCLEROTOMY LOCATION

6

6

6

### LIMBUS-TO-SCLEROTOMY DISTANCE


6

6

6

AGE	MINIMUM CILIARY BODY LENGTH (AIELLO ET AL <sup>1</sup> )	MINIMUM LIMBUS- TO-ORA SERRATA DISTANCE	CALCULATED	APPLIED <sup>*</sup>
0–6 mo	2.60 mm	2.95 mm	1.45 mm	1.5 mm <sup>‡</sup>
6–12 mo	2.86 mm	3.21 mm	1.71 mm	2.0 mm
1–2 yr	3.28 mm	3.63 mm	2.13 mm	2.5 mm
2–3 yr	3.75 mm	4.10 mm	2.60 mm	3.0 mm‡
Adult	4.60 mm	4.95 mm	3.45 mm	3.5 mm <sup>§</sup>

Aiello AL, Tran VT, Rao NA. Postnatal development of the ciliary body and pars plana: a morphometric study in childhood. Arch Ophthalmol 1992;110:802-805.



## When Lensectomy is Planned

- 1. İris root entry: Iris problems
- 2. Limbal entry:

6

6

6

6

6

Corneal distortion, endothelial damage


10/0 sutur needed (EUGA for removal)


Advantages:


- Chantotomy not needed
- Conjunctiva is protected


Peripheral retinal damage is avoided






















## 23G-with cannula Stage 4a ROP


## Prof. Dr. Şengül Özdek





## Stage 4A-without trockars














•



# Stage 5






## Surgery for Cicatricial ROP

Olgu/Cinsi yet/Göz	Doğum Haftası/Kilosu (hft/gr)	Cerrahi Yaşı (ay)	Preop GK	Preop Tedavi	Cerrahi	Komplikasyon	Takip Süresi(ay)	Anatomik Başarı	Maküler katlantı Preop/Postop	Postop GK
1/E/Sol	28/1060	6	×	8	PPV+PPL		24	Kısmi Başarı	+/+	×
2/K/Sol	25/650	38	IOT(-)	LFK	PPV	2	5	+	-/-	1mps
3/E/Sol	29/1100	59	PPEH	LFK	PPV+PPL	latrojenik delik	1	•	-/-	PPEH
4/K/Sol	30/1370	10	10T(·)		PPV		3	Kısmi Başarı	+/+	10T(+)
5/K/Sol	28/1500	11	10T(-)		PPV+PPL		20	+	+/-	0.1
6/E/Sağ	28/850	79	0.2	33	PPV	55	40	+	+/-	0.7
6/E/Sol	28/850	81	0.05	2	PPV	2	40	+	+/-	0.3
7/K/Sağ	28/1800	4	10T(-)	10	PPV	1	24	+	+/-	0.05
8/K/Sağ	30/1290	104	1mps	8	PPV	10	6	Kısmi Başarı	+/+	0.05
9/K/Sağ	28/990	2	10T(-)	LFK+İVB	PPV+PPL	75	19	Kısmi Başarı	-/-	IOT(-)
9/K/Sol	28/990	2	10T(-)	LFK+İVB	PPV+PPL	Geç <u>Vit</u> Hem/RRD	19		-/-	IOT(-)
10/K/Sağ	28/900	213	1mps	2	PPV+PPL		12	Kısmi Başarı	+/+	1mps

## 6,5 y, M, VA:0.1/0.15 28 wk 1300 gr, No treatment before

6

6



Cicatricial ROP



### Postop 3rd year VA: 0.7

6


6


6

6

6

6





200 µm

GK: 0.7

04.05.2015, OS IR&OCT 30° ART [HS] ART(10) Q: 25

200 µm

HEIDELBEIG

6

6

6

6

6

## Postop 3rd year: VA: 0.3

6

6

6

6


6

6

## GK: 0.3

04.05.2015, OD IR&OCT 30° ART [HS] ART(9) Q: 22

200 µm



6

6


6


6

6

6

HEIDELBEIG Engineering









6

6

• Mostly AD inheritance

6


6

6

6

6

- NDP, FZD4, LRP5, TSPAN12, ZNF408: (Wnt-NORRIN signal pathway) defective genes
  - Retinal angiogenezis is defective: Vascular differentiation is insufficient
  - Peripheral retinal vascularization is incomplete
  - 21-64% RD: Tractional or exudative




# FEVR-Treatment 6y old, F, bilat TRD, VA: 0.05





2/02/2016 10:24:56.4

J/05/2016 10:24:52.8


# FEVR-Treatment VA: Preop:0.05 Postop: 0.3



















### COATS Classification-Shields

1. ONLY TELANGIECTASIS

2. TELANGIECTASIS & EXUDATION

A. Extrafoveal Exudation

- B. Foveal Exudation
- 3. + EXUDATIVE RD
  - A. subtotal
  - B. total
- 4. + NVG



6

6

6

6

6

6

5. END STAGE DISEASE (Painful red eye)

# COATS-Treatment

- Primary Treatment: Laser (Stage 1,2,3)
- Cryotherapy: Stage 3

1

6


6

6

6


6

- Surgery: Stage 3-4
  - External Drainage Cryo or Laser
  - Anti-VEGF or Ozurdex
  - PPV-External Drainage
  - Retinotomy for internal drainage should absolutely be avoided!




## COATS Treatment End stage


- Surgery to preserve the globe in advanced cases (for cosmesis and comfort)
  - 16% of eyes in Coats disease are enucleated because of painful eye.



### 9 mo old boy, Stage 4 Coats Drainage Cryo



### 9 mo old boy, Stage 4 Coats Drainage Cryo







BOZKURT,AHMET BERK 01-01-2010 23-10-2015


OD Montage




Ozdek S et al. Spontaneous Regression in Two Unusual Cases of Advanced Coats' Disease. J Pediatr Ophthalmol Strabismus. 2010 Mar 26:1-4.


























### Radial iris vessels (hairpin-loops)



# Goals of Surgery for PFV

To get acceptable anatomical and functional results

- Clear the media in order to prevent amblyobia
- Relieve tractional forces
  - To prevent TRD, glaucoma, Phthisis bulbi
  - To let the eye to have the opportunity to grow


#### Anatomical diferences in Anterior PFV

- PP not developed,
  - 🔮 No zonules,
  - Elongated ciliary processes






Anterior fibrovascular structure may be continuous with retina!








# PFV-anterior retinal elongation



### Tips: Pigmented plaques Nasal and inferior location






# PFV-anterior retinal elongation




### Total excision vs leaving some part of FV tissue?



FV tissue contracts and causes pupillary obliteration or Peripheral RD within years leading total TRD



# Leaving peripheral part of FV tissue....pupillary obliteration



## Patients and Methods

- 29 eyes of 28 patients with PFV (last 6 years)
- 19 (67.1%) were male

6

6

6

6


- 14 eyes (47.7%): Anterior PFV
- 10 eyes (34.5%): Posterior PFV
- 5 eyes (17.2%): Mixed type
  - Median follow-up:14 months (6 months to 5.5 years)



• Anterior retinal elongation: 64.3% of anterior PFV.

- 84.6% of anterior PFV cases resulted in anatomic success.
- Final VA: 20/200 or better in 38.5% of anterior PFV cases.

# Complications



\*includes anterior and combined cases.

www.ankararetina.com

6


Fischer exact test.


OLS


## Results

6


PFV patients who has more extensive anterior disease tend to have a higher
 risk of overall complications than
 patients with localized fibrovascular tissue.










### PFV-posterior-postop










### CONGENITAL X-LINKED RETINOSCISIS CXLR






- Recurrent vitreous hemorrhages
- RRD



### 8 mo old, M, Bilateral Vit Hem,





## 21y, M, VA: 0.3 (LE) Bilat PPV 15 yr earlier, RE: FB




04.07.2014, OS BAF 30° ART(44)


















#### 14 y old, Cerebellar hemangioma (operated) VA: HM Fundus: Vit Hem-TRD



#### RETINAL HEMANGIOBLASTOMA 3 years postop





6

6

10/02/2017 13:26:10.7

#### **RETINAL HEMANGIOBLASTOMA** Follow ups with FA every 4-6 months





### SURGERY IS AN ART

www.sengulozdek.com sengulozdek@gmail.com

